Rhabdomyolysis a result of azithromycin and statins: An unrecognized interaction

British Journal of Clinical Pharmacology

Volumn 68, Issue 3, 2009, Pages 427-434

  Strandell, Johanna ^a,b   Bate, Andrew ^a,c   Hägg, Staffan ^b   Edwards, I Ralph ^a  

^a PFIZER INC   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

Adverse drug reaction reporting systems; Azithromycin; Disproportionality measure; Drug interaction; Statins; WHO ADR database

Indexed keywords

ATORVASTATIN; AZITHROMYCIN; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG USE; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RHABDOMYOLYSIS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; AZITHROMYCIN; DATABASES, FACTUAL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MIDDLE AGED; PRAVASTATIN; PYRIDINES; PYRROLES; RHABDOMYOLYSIS; SIMVASTATIN;

EID: 69949150268     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03473.x     Document Type: Article

References (39)

1. Lane R, Phillips M. Rhabdomyolysis. BMJ 2003 327 : 115 116.
2. Evans M, Rees A. Effects of HMG-coa reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002 25 : 649 663.
3. Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Curr Opin Lipidol 2002 13 : 637 644.
4. Molden E, Andersson KS, Jacobsen D. Interactions between statins and macrolide antibiotics. Tidsskr Nor Laegeforen 2007 127 : 1660 1661.
5. Thompson Micromedex Database. DrugDex. 2008.
6. Datapharm Communications Ltd. The Medicines Compendium. Electronic Medicine Compendium, Electronic version, 2008.
7. Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother 2000 34 : 495 513.
8. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995 29 : 906 917.
9. Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 2002 42 : 444 449.
10. Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997 31 : 859 863.
11. Skrabal MZ, Stading JA, Cannella CA, Monaghan MS. Two cases of rhabdomyolysis associated with high-dose simvastatin. Am J Health Syst Pharm 2003 60 : 578 581.
12. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RMA. Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998 54 : 315 321.
13. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007 82 : 157 166.
14. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994 10 : 93 102.
15. Egberts AC, Meyboom RH, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 2002 25 : 453 458.
16. van Puijenbroek EP, Egberts AC, Heerdink ER, Leufkens HG. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 2000 56 : 733 738.
17. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002 25 : 381 392.
18. Noren GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stat Med 2008 27 : 3057 3070.
19. Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol 2001 28 : 1180 1187.
20. Strandell J, Bate A, Lindquist M, Edwards IR. Drug interaction signal detection in spontaneous reports. Pharmacoepidemiol Drug Saf 2007 16 (Suppl. 2 S256 (540).
21. Edwards IR, Olsson S. WHO programme - global monitoring. In : Pharmacovigilance, eds Mann RD, Andrews EB. Chichester : John Wiley & Sons, Ltd, 2002 169 182.
22. Bate A, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 2008 22 : 127 140.
23. Ståhl M, Lindquist M, Edwards IR, Brown EG. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol Drug Saf 2004 13 : 355 363.
24. Lindquist M. Use of triage strategies in the WHO signal-detection process. Drug Saf 2007 30 : 635 637.
25. Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol 2007 64 : 489 495.
26. Norén GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. Data Mining Knowl Discovery 2007 14 : 305 328.
27. Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 2000 23 : 533 542.
28. Bentzen N, Bridges-Webb C. An international glossary for general/family practice. Fam Pract 1995 12 : 341 369.
29. Kogan ADOS. Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 1990 66 : 294 296.
30. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005 165 : 2671 2676.
31. Crum-Cianflone NF. Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev 2008 21 : 473 494.
32. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997 17 : 374 389.
33. Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007 30 : 891 898.
34. McAdams M, Staffa J, Dal Pan G. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2008 17 : 229 239.
35. Strandell J, Bate A, Lindquist M, Edwards IR Swedish, Finnish, Interaction X-referencing Drug-Drug Interaction Database (SFINX Group). Drug-drug interactions - a preventable patient safety issue? Br J Clin Pharmacol 2008 65 : 144 146.
36. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006 80 : 565 581.
37. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000 50 : 285 295.
38. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008 47 : 463 474.
39. El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. The effect of azithromycin on ivermectin pharmacokinetics - a population pharmacokinetic model analysis. PLoS Negl Trop Dis 2008 2 : e236.